dc.contributor.author |
Islamov R. |
|
dc.contributor.author |
Rizvanov A. |
|
dc.contributor.author |
Mukhamedyarov M. |
|
dc.contributor.author |
Salafutdinov I. |
|
dc.contributor.author |
Garanina E. |
|
dc.contributor.author |
Fedotova V. |
|
dc.contributor.author |
Solovyeva V. |
|
dc.contributor.author |
Mukhamedshina Y. |
|
dc.contributor.author |
Safiullov Z. |
|
dc.contributor.author |
Izmailov A. |
|
dc.contributor.author |
Guseva D. |
|
dc.contributor.author |
Zefirov A. |
|
dc.contributor.author |
Kiyasov A. |
|
dc.contributor.author |
Palotás A. |
|
dc.date.accessioned |
2018-09-18T20:23:51Z |
|
dc.date.available |
2018-09-18T20:23:51Z |
|
dc.date.issued |
2015 |
|
dc.identifier.issn |
1566-5232 |
|
dc.identifier.uri |
https://dspace.kpfu.ru/xmlui/handle/net/139454 |
|
dc.description.abstract |
© 2015 Bentham Science Publishers. Amyotrophic lateral sclerosis (ALS) is an incurable, chronic, fatal neuro-degenerative disease characterized by progressive loss of moto-neurons and paralysis of skeletal muscles. Reactivating dysfunctional areas is under earnest investigation utilizing various approaches. Here we present an innovative gene-cell construct aimed at reviving inert structure and function. Human umbilical cord blood cells (hUCBCs) transduced with adeno-viral vectors encoding human VEGF, GDNF and/or NCAM genes were transplanted into transgenic ALS mice models. Significant improvement in behavioral performance (open-field and grip-strength tests), as well as increased life-span was observed in rodents treated with NCAM-VEGF or NCAM-GDNF co-transfected cells. Active trans-gene expression was found in the spinal cord of ALS mice 10 weeks after delivering genetically modified hUCBCs, and cells were detectable even 5 months following transplantation. Our gene-cell therapy model yielded prominent symptomatic control and prolonged life-time in ALS. Incredible survivability of xeno-transpanted cells was also observed without any immune-suppression. These results suggest that engineered hUCBCs may offer effective gene-cell therapy in ALS. |
|
dc.relation.ispartofseries |
Current Gene Therapy |
|
dc.subject |
Adeno-virus |
|
dc.subject |
Amyotrophic lateral sclerosis (ALS) |
|
dc.subject |
Gene-cell therapy |
|
dc.subject |
Glial cell-derived neuro-trophic factor (GDNF) |
|
dc.subject |
Human umbilical cord blood cell (hUCBC) |
|
dc.subject |
Human umbilical cord blood mono-nuclear cell (hUCB-MC) |
|
dc.subject |
Neural cell adhesion molecule (NCAM) |
|
dc.subject |
Vascular endothelial growth factor (VEGF) |
|
dc.subject |
Viral vector |
|
dc.title |
Symptomatic improvement, increased life-span and sustained cell homing in amyotrophic lateral sclerosis after transplantation of human umbilical cord blood cells genetically modified with adeno-viral vectors expressing a neuro-protective factor and a neural cell adhesion molecule |
|
dc.type |
Article |
|
dc.relation.ispartofseries-issue |
2 |
|
dc.relation.ispartofseries-volume |
15 |
|
dc.collection |
Публикации сотрудников КФУ |
|
dc.relation.startpage |
266 |
|
dc.source.id |
SCOPUS15665232-2015-15-2-SID84928944466 |
|